At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 32 enrolled
Drug / intervention
Anakinra +1 moredrug
Likely dose
Anakinra 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Treatment of Cytokine Storm Syndrome in Covid-19
In Brief
A Phase 3 clinical trial evaluating Anakinra and Normal saline for Cytokine Storm and COVID-19. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytokine Storm, COVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartAug 2020
Primary CompletionDec 2021
Study CompletionJun 2023
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartAug 1, 2020
Primary CompletionDec 31, 2021
Study CompletionJun 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.2 years ago
Interventions
Anakinradrug
The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
Normal salinedrug
The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days